Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Covering sudden costs requires a quick plan: balance cash, credit options, and smart cuts to stay on track.
13,220 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
With the 2026 midterms approaching, crypto markets face shifting liquidity and policy bets that could drive a notable...
A three-way bid for Warner Bros. Discovery produced three market winners, reshaping how investors view streaming, stu...
When a senior executive sells thousands of shares, investors often jump to conclusions. This article breaks down what...
Prediction-market trading on Iran’s leadership surged as tensions flared, but unverified rumors triggered rapid price...
Traders chase BOIL as natural gas whipsaws drive outsized moves, despite heavy losses over the past year. The 2x leve...
As the CLARITY Act stalls in the Senate, the Trump administration escalates pressure on banks to unlock crypto bankin...
Pi Network's PI token hits a three-week high, but a trio of risk factors suggests a pullback could be on the horizon....
A new stake in Vista Energy signals rising institutional interest in the energy sector. This article breaks down why ...
The U.S. signals broader military targets in Iran as tensions flare, sending oil higher and putting pressure on house...
Palantir’s AI-enabled analytics engine has fueled growth, but the stock faces multiple headwinds. This article lays o...
Institutional buyers are quietly backing a select set of artificial intelligence (ai) stock for 2026. This deep dive ...